『Touching Base』のカバーアート

Touching Base

Touching Base

著者: Genetic Engineering & Biotechnology News (GEN)
無料で聴く

このコンテンツについて

Touching Base is the dynamic podcast series from the editors of GEN (Genetic Engineering & Biotechnology News). Each episode features a rotating cast of senior editors including John Sterling, Kevin Davies, Julianna LeMieux, Alex Philippidis, Uduak Thomas, Corinna Singleman and Fay Lin who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.

Hosted on Acast. See acast.com/privacy for more information.

Genetic Engineering & Biotechnology News (GEN)
政治・政府 生物科学 科学
エピソード
  • Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs
    2025/07/25

    Sarepta has temporarily paused shipments of Elevidys, its FDA-approved treatment for Duchenne muscular dystrophy. In this episode of GEN's Touching Base, we discuss the company’s response to the tragedies associated with its DMD therapy as well as with a new therapy for limb-girdle muscular dystrophy. Also in this episode, big updates from AstraZeneca including a $50 billion investment in U.S. manufacturing and R&D, a heartwarming story about preventing mitochondrial disease involving eight babies from the U.K., and from the lab of Nobel Prize winner David Baker, PhD, AI that designs drugs for previously “undruggable” proteins.


    Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.


    Listed below are links to the GEN stories referenced in this episode of Touching Base:


    About Face: Sarepta to Pause Elevidys Shipments Temporarily

    By Alex Philippidis, GEN Edge, July 21, 2025


    StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies

    By Alex Philippidis, GEN Edge, July 20, 2025


    Sarepta Axes 500, 36% of Workforce, in Restructuring after DMD Patient Deaths

    By Alex Philippidis, GEN Edge, July 16, 2025


    AstraZeneca Commits $50B More to U.S. Manufacturing, R&D Projects

    By Alex Philippidis, GEN Edge, July 22, 2025


    AstraZeneca’s New $300M Plant Provides Control of Cell Therapy Production

    By Gareth John Macdonald, GEN, May 14, 2025

    Beyond Baby KJ: Next Steps in Manufacturing Genome Editing Cures

    GEN Live, July 30, 2025


    Mitochondrial Disease Milestone: Eight Babies Born Free of Disease via Pronuclear Transfer

    By Julianna LeMieux, PhD GEN, July 16, 2025


    Undruggable No More: AI Hits Disordered Proteins, Unlocks Therapy Targets

    By Fay Lin, PhD GEN, July 18, 2025

    Hosted on Acast. See acast.com/privacy for more information.

    続きを読む 一部表示
    43 分
  • Merck Acquires Verona, Virtual Cell Challenge, Gene Therapy Restores Hearing
    2025/07/11

    Merck & Co. has acquired Verona Pharma for $10 billion in a deal designed to expand the pharma giant’s portfolio of cardio-pulmonary disease treatments. In a step toward virtual cell benchmarking, the Arc Institute has launched the Virtual Cell Challenge to evaluate the ability of transcriptome AI models to generalize to new cell contexts for therapeutic applications. Fujifilm rebrands life science companies to position itself as a drug development leader. Additionally, AAV-OTOF gene therapy shows promise in restoring hearing loss while a new proteomics tool gleams insight into telomere repair. We wrap up our episode with highlights from BIO 2025, as FDA Commissioner Martin Makary, MD, shared his vision for a “New FDA” focused on accelerating drug applications, industry partnerships, and applying AI.


    Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

    Listed below are links to the GEN stories referenced in this episode of Touching Base:

    Merck to Acquire Verona Pharma for $10B, Adding Fast-Growing COPD Drug

    By Alex Philippidis, GEN Edge, July 9, 2025


    Arc Institute Launces Virtual Cell Challenge to Accelerate AI Model Development

    By Fay Lin, PhD, GEN Edge, June 26, 2025


    End-to-End: Fujifilm Rebrands Life Sciences Companies, Positioning Itself as Drug Development Cycle Leader

    By Alex Philippidis, GEN Edge, July 8, 2025

    AAV-OTOF Gene Therapy Trial Restores Hearing in Both Children and Adults

    By GEN, July 7, 2025

    Proteomics Tool Sheds Light on Cancer Cells’ Telomere Repair Tactics

    By GEN, July 7, 2025

    Makary Calls for “New FDA” at BIO; Defends Agency’s Spring Job Cuts

    By Alex Philippidis, GEN Edge, June 18, 2025


    Cell and Gene Therapy Leaders Tell FDA: “Believe in American Solutions”

    By Kevin Davies, PhD, and Alex Philippidis, GEN Edge, June 5, 2025

    Behind the Breakthroughs Podcast

    Hosted by Jonathan D. Grinstein, PhD

    Hosted on Acast. See acast.com/privacy for more information.

    続きを読む 一部表示
    32 分
  • BIO 2025, Huge Virtual Cell Dataset, AI-Designed De Novo Proteins
    2025/06/18

    Acast


    BIO 2025, Huge Virtual Cell Dataset, AI-Designed De Novo Proteins


    BIO 2025 is off and running. GEN editors discuss the size and scope of the bustling conference hall and share excitement about the week’s talks and panels. News from BIO includes the announcement of Lilly’s acquisition of Verve Therapeutics. Editors discuss the implications of industry-backed therapeutics amid cautious investors and public sentiment. In the realm of AI, Xaira Therapeutics, a $1 billion-backed AI drug discovery unicorn, has capped its first year by releasing the largest publicly available Perturb-seq dataset to support its virtual cell initiative. Additionally, AlphaDesign, a new AI-driven framework, accelerates the creation of functional de novo proteins, moving protein design toward custom therapeutics and precision medicine.

    Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Uduak Thomas, and Fay Lin, PhD, for a discussion of the latest biotech and biopharma news.

    Listed below are links to the GEN stories referenced in this episode of Touching Base

    Lilly to Acquire Verve Therapeutics for Up to $1.3B

    By Alex Philippidis, GEN Edge, June 17, 2025

    Second DMD Patient Dies After Treatment with Sarepta Gene Therapy

    By Alex Philippidis, GEN Edge, June 15, 2025


    Danon Disease Patient Dies in Rocket Gene Therapy Trial

    By Alex Philippidis, GEN Edge, May 27, 2025


    Xaira Therapeutics Releases Largest Perturb-Seq Dataset to Power the Virtual Cell

    By Fay Lin, GEN Edge, June17, 2025


    AI-Designed Proteins Created De Novo with New AlphaDesign

    GEN, June 17, 2025

    Hosted on Acast. See acast.com/privacy for more information.

    続きを読む 一部表示
    29 分

Touching Baseに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。